Nuo Therapeutics, Inc. – OTC:AURX

Add to watchlist

$1.7

+0.16

+11.11%

Market open

Closed in about 5 hours

+313.51%

month

+313.51%

quarter

+155.00%

year

Market Cap	71.05M
Enterprise value	110.59M

P/E	-30.56
EV/Sales	2891.37
EV/EBITDA	-49.11
Price/Sales	2957.36
Price/Book	35.90
PEG ratio	0.27
EPS	-0.07

Revenue	782.00K
EBITDA	-2.91M
Income	-3.02M
Revenue Q/Q	283.92%
Revenue Y/Y	351.11%

Profit margin	-6020.62%
Oper. margin	-6400.21%
Gross margin	83.02%
EBIT margin	-6400.21%
EBITDA margin	-372.81%

Get more financial ratios!

Every financial ratio you might need
10 years history
Forward ratios (Analysts estimates)

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

Nuo Therapeutics, Inc. (OTC:AURX): Profit margin
Jun 2023	118.16K	-871.88K	-737.83%
Sep 2023	232.24K	-790.64K	-340.44%
Dec 2023	197.01K	-653.15K	-331.53%
Mar 2024	234.57K	-708.78K	-302.15%

Nuo Therapeutics, Inc. (OTC:AURX): Debt to assets
Jun 2023	1385279	914.44K	66.01%
Sep 2023	1599902	873.18K	54.58%
Dec 2023	1877880	838.73K	44.66%
Mar 2024	1242833	909.38K	73.17%

Nuo Therapeutics, Inc. (OTC:AURX): Cash Flow
Jun 2023	-905.89K	0	0
Sep 2023	-794.88K	-1.90K	1.03M
Dec 2023	-671.40K	0	962.5K
Mar 2024	-562.44K	0	0

Nuo Therapeutics alternative data

Nuo Therapeutics, Inc. (OTC:AURX): Employee count
Aug 2023	10
Sep 2023	10
Oct 2023	10
Nov 2023	10
Dec 2023	10
Jan 2024	10
Feb 2024	10
Mar 2024	10
Apr 2024	10
May 2024	9
Jun 2024	9
Jul 2024	9

Nuo Therapeutics
Hedge Funds Holdings Q4 2022

0.02% 0.00%

of AURX is owned by hedge funds

1 +0

hedge funds hold AURX stock

4.7K +0

shares is hold by hedge funds

AURX hedge funds holdings changes

Nuo Therapeutics
Insider Trading

Nuo Therapeutics, Inc. (OTC:AURX): Insider trades (number of shares)
Period	Buy	Sel
Dec 2023	150000	0
May 2024	100000	0
Sep 2024	125000	0

Transaction	Date	Insider	Security	Shares	Price per share	Total value
Option	15 Nov 2024	PITTMAN SCOTT M. director, 10 percent owner: director, 10 percent owner:	Common Stock	33,334	$0.5	$16,667
Option	15 Nov 2024	PITTMAN SCOTT M. director, 10 percent owner: director, 10 percent owner:	Common Stock	62,500	$0.4	$25,000
Option	15 Nov 2024	PITTMAN SCOTT M. director, 10 percent owner: director, 10 percent owner:	Common Stock	121,875	$0.4	$48,750
Purchase	18 Sep 2024	SHEEDY CHARLES E 10 percent owner 10 percent owner	Common Stock	125,000	$0.75	$93,750
Purchase	20 May 2024	SHEEDY CHARLES E 10 percent owner 10 percent owner	Common Stock	100,000	$0.75	$75,000
Purchase	19 Dec 2023	SHEEDY CHARLES E 10 percent owner 10 percent owner	Common Stock	150,000	$0.5	$75,000
Purchase	1 Aug 2023	SHEEDY CHARLES E 10 percent owner 10 percent owner	Common Stock	62,500	$2	$125,000
Sale	9 Nov 2022	JORDEN DAVID EMERSON officer: CEO/CFO officer: CEO/CFO	Common Stock	5,000	$1.5	$7,500
Sale	9 Nov 2022	JORDEN DAVID EMERSON officer: CEO/CFO officer: CEO/CFO	Common Stock	7,000	$1.5	$10,500
Sale	9 Nov 2022	JORDEN DAVID EMERSON officer: CEO/CFO officer: CEO/CFO	Common Stock	10,000	$1.5	$15,000

AURX insider trading transactions

Frequently Asked Questions (FAQ)

What's the price of Nuo Therapeutics stock today?

One share of Nuo Therapeutics stock can currently be purchased for approximately $1.7.
When is Nuo Therapeutics's next earnings date?

Unfortunately, Nuo Therapeutics's (AURX) next earnings date is currently unknown.
Does Nuo Therapeutics pay dividends?

No, Nuo Therapeutics does not pay dividends.
How much money does Nuo Therapeutics make?

Nuo Therapeutics has a market capitalization of 71.05M and it's past years’ income statements indicate that its last revenue has increased compared to the previous period by 442.12% to 608.53K US dollars.
What is Nuo Therapeutics's stock symbol?

Nuo Therapeutics, Inc. is traded on the OTC under the ticker symbol "AURX".
What is Nuo Therapeutics's primary industry?

Company operates in the Healthcare sector and Biotechnology industry.
How do i buy shares of Nuo Therapeutics?

Shares of Nuo Therapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
How many employees does Nuo Therapeutics have?

As Jul 2024, Nuo Therapeutics employs 9 workers, which is 10% less then previous quarter.
What is Nuo Therapeutics's official website?

The official website for Nuo Therapeutics is nuot.com.
Where are Nuo Therapeutics's headquarters?

Nuo Therapeutics is headquartered at 8285 El Rio, Houston, TX.
How can i contact Nuo Therapeutics?

Nuo Therapeutics's mailing address is 8285 El Rio, Houston, TX and company can be reached via phone at +34 63964770.

Nuo Therapeutics, Inc.

nuot.com

Exchange:

OTC

Full time employees:

Industry:

Biotechnology

Sector:

Healthcare

Nuo Therapeutics, Inc., a regenerative therapies company, develops, commercializes, and markets cell-based technologies that harness the regenerative capacity of the human body to trigger natural healing primarily in the United States. Its technology separates autologous blood to produce a platelet based therapy for the chronic wound care market. The company was formerly known as Cytomedix, Inc. and changed its name to Nuo Therapeutics, Inc. in November 2014. Nuo Therapeutics, Inc. was founded in 1998 and is based in Houston, Texas.

+34 63964770

8285 El Rio
Houston, TX 77054

CIK: 0001091596
:
: